title: Response to the letter concerning the article "Rivaroxaban in secondary cardiogenic stroke prevention: two-year single-centre experience based on follow-up of 209 patients".
authors.affiliation: alasek@gcm.pl.
authors.forename: Anetta
authors.initials: A
authors.lastname: Lasek-Bal
authors.forename: Tomasz
authors.initials: T
authors.lastname: Urbanek
authors.forename: Przemysław
authors.initials: P
authors.lastname: Puz
authors.forename: Marek
authors.initials: M
authors.lastname: Piekarski
mesh_terms: D000925:Anticoagulants / Q000627:therapeutic use; D001281:Atrial Fibrillation; D065427:Factor Xa Inhibitors / Q000627:therapeutic use; D005500:Follow-Up Studies; D006801:Humans; D009025:Morpholines / Q000627:therapeutic use; D000069552:Rivaroxaban; D055502:Secondary Prevention; D020521:Stroke; D013876:Thiophenes / Q000627:therapeutic use; D016896:Treatment Outcome; D014859:Warfarin / Q000627:therapeutic use
chemical_list: D000925:Anticoagulants; D065427:Factor Xa Inhibitors; D009025:Morpholines; D013876:Thiophenes; D014859:Warfarin; D000069552:Rivaroxaban